Bristol Myers Squibb Stock Rises 1.24% Despite Camzyos Setback, Ranks 98th in Trading Volume

On April 14, 2025, Bristol Myers Squibb (BMY) saw a trading volume of 7.32 billion, ranking 98th in the day's stock market activity. The stock rose by 1.24%, marking its second consecutive day of gains, with a total increase of 1.74% over the past two days.

Bristol Myers Squibb's stock experienced a significant decline late Monday after its drug, Camzyos, failed to meet the primary goals in a heart disease study. This setback led to a drop in the company's stock price, also affecting Cytokinetics, which was pulled down by the news.

The failure of Camzyos to significantly improve functional capacity and symptoms in patients with a type of heart disease was a major disappointment. This outcome underscores the challenges faced by pharmaceutical companies in developing effective treatments for complex conditions.